{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:26:34Z","timestamp":1790868394649,"version":"4.1.0"},"reference-count":85,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T00:00:00Z","timestamp":1664409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015190","name":"Houston Methodist Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015190","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Ophthalmol."],"abstract":"<jats:p>Optic pathway gliomas (OPG) are primary tumors of the optic nerve, chiasm, and\/or tract that can be associated with neurofibromatosis type 1 (NF1). OPG generally have a benign histopathology, but a variable clinical course. Observation is generally recommended at initial diagnosis if vision is stable or normal for age, however, treatment may include chemotherapy, radiotherapy, or surgery in select cases. This manuscript reviews the literature on OPG with an emphasis on recent developments in treatment.<\/jats:p>","DOI":"10.3389\/fopht.2022.992673","type":"journal-article","created":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T04:17:26Z","timestamp":1664425046000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Novel treatments in optic pathway gliomas"],"prefix":"10.3389","volume":"2","author":[{"given":"Akash","family":"Maheshwari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Pakravan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaow","family":"Charoenkijkajorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon J.","family":"Beres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew G.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,29]]},"reference":[{"key":"B1","unstructured":"Optic pathway glioma [Internet]"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2020.03.053","article-title":"Neurofibromatosis type 1-associated optic pathway glioma in children: A follow-up of 10 years or more","volume":"221","author":"Kinori","year":"2021","journal-title":"Am J Ophthalmol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/sj.eye.6702379","article-title":"Optic glioma warranting treatment in children","volume":"20","author":"Kaufman","year":"2006","journal-title":"Eye"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.20655","article-title":"Optic pathway gliomas","volume":"46","author":"Jahraus","year":"2006","journal-title":"Pediatr Blood Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2217\/cns.12.47","article-title":"Optic pathway gliomas: A review","volume":"2","author":"Fried","year":"2013","journal-title":"CNS Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/eye.1997.215","article-title":"The clinical presentation of children with tumours affecting the anterior visual pathways","volume":"11","author":"Suharwardy","year":"1997","journal-title":"Eye"},{"key":"B7","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-540-32708-0_12","article-title":"Brain tumors relevant to clinical neuro-ophthalmology","volume-title":"Clinical neuro-ophthalmology [Internet]","author":"Leo-Kottler","year":"2007"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19970701)80:1%3C142::AID-CNCR19%3E3.0.CO;2-Y","article-title":"Diencephalic syndrome and disseminated juvenile pilocytic astrocytomas of the hypothalamic-optic chiasm region","volume":"80","author":"Perilongo","year":"1997","journal-title":"Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"E2","DOI":"10.3171\/FOC-07\/11\/E2.","article-title":"Optic pathway gliomas: A review","volume":"23","author":"Binning","year":"2007","journal-title":"Neurosurg Focus"},{"key":"B10","volume-title":"Optic pathway glioma [Internet]","author":"Gaillard","year":"2009"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s004310000531","article-title":"When do children with optic pathway tumours need treatment? An oncological perspective in 106 patients treated in a single centre","volume":"159","author":"Grill","year":"2000","journal-title":"Eur J Pediatr"},{"key":"B12","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1177\/0883073817739509","article-title":"Optic pathway gliomas in neurofibromatosis type 1","volume":"33","author":"Campen","year":"2018","journal-title":"J Child Neurol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21107","article-title":"Optic pathway gliomas in neurofibromatosis-1: Controversies and recommendations","volume":"61","author":"Listernick","year":"2007","journal-title":"Ann Neurol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.3390\/cancers11111790","article-title":"Optic pathway glioma in type 1 neurofibromatosis: Review of its pathogenesis, diagnostic assessment, and treatment recommendations","volume":"11","author":"Cassina","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B15","unstructured":"RechtL Optic pathway glioma [Internet]2022"},{"key":"B16","volume-title":"Optic nerve glioma [Internet]","author":"Huang","year":"2022"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(14)76780-7","article-title":"Magnetic resonance imaging signs of optic nerve gliomas in neurofibromatosis 1","volume":"111","author":"Imes","year":"1991","journal-title":"Am J Ophthalmol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1080\/01658100802419912","article-title":"Pseudo-cerebrospinal fluid sign on magnetic resonance imaging in a patient with a presumed optic nerve sheath meningioma","volume":"32","author":"Zhang","year":"2008","journal-title":"Neuro Ophthalmol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(99)00337-5","article-title":"Proton radiation therapy (prt) for pediatric optic pathway gliomas: Comparison with 3d planned conventional photons and a standard photon technique","volume":"45","author":"Fuss","year":"1999","journal-title":"Int J Radiat Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1159\/000028996","article-title":"Optic pathway hypothalamic gliomas in children under three years of age: The role of chemotherapy","volume":"33","author":"Silva","year":"2000","journal-title":"Pediatr Neurosurg"},{"key":"B21","article-title":"Grading glioma tumors using OWL-DL and NCI thesaurus","author":"Marquet","year":"2007"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.789856\/full","article-title":"Epidemiology and survival of patients with optic pathway gliomas: A population-based analysis","volume":"12","author":"Liu","year":"2022","journal-title":"Front Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0127676","article-title":"Mortality in children with optic pathway glioma treated with up-front BB-SFOP chemotherapy","volume":"10","author":"Rakotonjanahary","year":"2015","journal-title":"Alonso MM editor PloS One"},{"key":"B24","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1227\/01.NEU.0000097266.89676.25","article-title":"Pilocytic and pilomyxoid Hypothalamic\/Chiasmatic astrocytomas","volume":"54","author":"Komotar","year":"2004","journal-title":"Neurosurg"},{"key":"B25","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/nop\/npv016","article-title":"Survival trends of grade I, II, and III astrocytoma patients and associated clinical practice patterns between 1999 and 2010: A SEER-based analysis","volume":"3","author":"Dong","year":"2016","journal-title":"Neuro Oncol Pract"},{"key":"B26","article-title":"Malignant optic pathway glioma [Internet]","year":"2014","journal-title":"Am J Neuroradiol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s12886-017-0415-5","article-title":"Unilateral malignant optic glioma following glioblastoma multiforme in the young: A case report and literature review","volume":"17","author":"Lin","year":"2017","journal-title":"BMC Ophthalmol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-015-3045-8","article-title":"Malignant optic glioma \u2013 the spectrum of disease in a case series","volume":"253","author":"Traber","year":"2015","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"key":"B29","unstructured":"AlsuhaibaniA Al NajashiAH PinelesSL LeeAG YenM BurkatC Optic nerve glioma [Internet]2022"},{"key":"B30","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.3171\/FOC-07\/11\/E1","article-title":"Neuroophthalmological management of optic pathway gliomas","volume":"23","author":"Lee","year":"2007","journal-title":"Neurosurg Focus"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.36.6054","article-title":"Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: A report from the children\u2019s oncology group","volume":"30","author":"Ater","year":"2012","journal-title":"J Clin Oncol"},{"key":"B32","unstructured":"Cancer therapy evaluation program [Internet]. division of cancer treatment & diagnosis2022"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(78)90193-1","article-title":"Radiotherapy in the management of primary gliomas involving the intracranial optic nerves and chiasmt","volume":"4","author":"Harter","year":"1978","journal-title":"Int J Radiat Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-003-8104-0","article-title":"Current and future strategies in radiotherapy of childhood low-grade glioma of the brain","volume":"179","author":"Kortmann","year":"2003","journal-title":"Strahlentherapie und Onkol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/9585614","article-title":"Immunotherapies: Exploiting the immune system for cancer treatment","volume":"2018","author":"Koury","year":"2018","journal-title":"J Immunol Res"},{"key":"B36","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1080\/20014091084218","article-title":"Clinical uses of tumor markers: A critical review","volume":"38","author":"Duffy","year":"2001","journal-title":"Crit Rev Clin Lab Sci"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0000000000000587","article-title":"Current treatment of optic nerve gliomas","volume":"30","author":"Farazdaghi","year":"2019","journal-title":"Curr Opin Ophthalmol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.3390\/molecules22101551","article-title":"Current development status of MEK inhibitors","volume":"22","author":"Cheng","year":"2017","journal-title":"Molecules"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-01025-7","article-title":"MEK inhibitors for the treatment of non-small cell lung cancer","volume":"14","author":"Han","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/now282","article-title":"A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a pediatric brain tumor consortium (PBTC) study","volume":"19","author":"Banerjee","year":"2017","journal-title":"Neuro Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30277-3","article-title":"Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: A multicentre, phase 2 trial","volume":"20","author":"Fangusaro","year":"2019","journal-title":"Lancet Oncol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/35065000","article-title":"Mammalian MAP kinase signalling cascades","volume":"410","author":"Chang","year":"2001","journal-title":"Nat"},{"key":"B44","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13045-016-0258-1","article-title":"Functional and genetic screening of acute myeloid leukemia associated with mediastinal germ cell tumor identifies MEK inhibitor as an active clinical agent","volume":"9","author":"Leonard","year":"2016","journal-title":"J Hematol Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/now209","article-title":"Pediatric low-grade gliomas: Implications of the biologic era","volume":"19","author":"Packer","year":"2016","journal-title":"Neuro Oncol"},{"key":"B46","unstructured":"ShafferC AndertonK What is b-raf? [Internet]2022"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.22647","article-title":"Therapeutic resistance resulting from mutations in Raf\/MEK\/ERK and PI3K\/PTEN\/Akt\/mTOR signaling pathways","volume":"226","author":"McCubrey","year":"2011","journal-title":"J Cell Physiol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1200\/PO.19.00298","article-title":"Outcomes of BRAF V600E pediatric gliomas treated with targeted BRAF inhibition","author":"Nobre","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.8726","article-title":"Therapeutic and prognostic implications of BRAF V600E in pediatric low-grade gliomas","volume":"35","author":"Lassaletta","year":"2017","journal-title":"J Clin Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab164","article-title":"Selumetinib for optic pathway glioma: Seeing through the fog, (not yet) the end of the tunnel","volume":"23","author":"Ramaswamy","year":"2021","journal-title":"Neuro Oncol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.3390\/ijms20061483","article-title":"Targeting the ERK signaling pathway in melanoma","volume":"20","author":"Savoia","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.3390\/cancers12071823","article-title":"BRAF inhibitors: Molecular targeting and immunomodulatory actions","volume":"12","author":"Proietti","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B53","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1177\/1758834015616934","article-title":"Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy","volume":"8","author":"Eroglu","year":"2016","journal-title":"Ther Adv Med Oncol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1007\/s00381-018-3739-4","article-title":"Marked functional recovery and imaging response of refractory optic pathway glioma to BRAFV600E inhibitor therapy: A report of two cases","volume":"34","author":"Upadhyaya","year":"2018","journal-title":"Child\u2019s Nerv Syst"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaapos.2016.01.012","article-title":"Separation of outer retinal layers secondary to selumetinib","volume":"20","author":"Avery","year":"2016","journal-title":"J Am Assoc Pediatr Ophthalmol Strabismus"},{"key":"B56","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s12886-017-0541-0","article-title":"Ocular toxicity due to trametinib and dabrafenib","volume":"17","author":"Sarny","year":"2017","journal-title":"BMC Ophthalmol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2014.174","article-title":"Entering the mainstream of cancer treatment","volume":"11","author":"Rosenberg","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"B58","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.156.11.4154","article-title":"Regulation of CTLA-4 expression during T cell activation","volume":"156","author":"Perkins","year":"1996","journal-title":"J Immunol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2035","article-title":"T Cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat Immunol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.19.1.565","article-title":"CTLA-4-Mediated inhibition in regulation of T cell responses: Mechanisms and manipulation in tumor immunotherapy","volume":"19","author":"Chambers","year":"2001","journal-title":"Annu Rev Immunol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.679425\/full","article-title":"Immune checkpoint inhibitors in human glioma microenvironment","volume":"12","author":"Ghouzlani","year":"2021","journal-title":"Front Immunol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12935-019-1085-6","article-title":"CTLA-4 correlates with immune and clinical characteristics of glioma","volume":"20","author":"Liu","year":"2020","journal-title":"Cancer Cell Int"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.31661","article-title":"Expression of LAG-3 and efficacy of combination treatment with anti-LAG-3 and anti-PD-1 monoclonal antibodies in glioblastoma","volume":"143","author":"Harris-Bookman","year":"2018","journal-title":"Int J Cancer"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2016.4142","article-title":"Expression of the galectin-9-Tim-3 pathway in glioma tissues is associated with the clinical manifestations of glioma","volume":"11","author":"Liu","year":"2016","journal-title":"Oncol Lett"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drup.2015.02.002","article-title":"Overcoming the blood\u2013brain tumor barrier for effective glioblastoma treatment","volume":"19","author":"van Tellingen","year":"2015","journal-title":"Drug Resist Update"},{"key":"B66","doi-asserted-by":"publisher","first-page":"3850","DOI":"10.1038\/s41467-019-11719-3","article-title":"Blood\u2013brain barrier permeable nano immunoconjugates induce local immune responses for glioma therapy","volume":"10","author":"Galstyan","year":"2019","journal-title":"Nat Commun"},{"key":"B67","doi-asserted-by":"publisher","first-page":"20","DOI":"10.17925\/USOR.2007.02.00.20","article-title":"Bevacizumab for ophthalmic disease","volume":"2","author":"Collet","year":"2007","journal-title":"US Ophthalmic Rev"},{"key":"B68","unstructured":"KarthPA FeldmanBH ShahVA KimLA TripathyK LimJ Bevacizumab [Internet]2021"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3171\/ped.2006.104.5.314","article-title":"Vascularity and angiogenesis as predictors of growth in optic pathway\/hypothalamic gliomas","volume":"104","author":"Bartels","year":"2006","journal-title":"J Neurosurg Pediatr"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1023\/A:1006416003964","article-title":"VEGF in brain tumors","volume":"50","author":"Machein","year":"2000","journal-title":"J Neurooncol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/not154","article-title":"Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas\u2013a pediatric brain tumor consortium study","volume":"16","author":"Gururangan","year":"2014","journal-title":"Neuro Oncol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24297","article-title":"Long-term efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas","volume":"60","author":"Hwang","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"B73","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1001\/jamaophthalmol.2013.5819","article-title":"Marked recovery of vision in children with optic pathway gliomas treated with bevacizumab","volume":"132","author":"Avery","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27234","article-title":"Single-agent bevacizumab in the treatment of recurrent or refractory pediatric low-grade glioma: A single institutional experience","volume":"65","author":"Gorsi","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"B75","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/cam4.1799","article-title":"Use of bevacizumab as a single agent or in adjunct with traditional chemotherapy regimens in children with unresectable or progressive low-grade glioma","volume":"8","author":"Zhukova","year":"2019","journal-title":"Cancer Med"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24066","article-title":"Bevacizumab and irinotecan in children with recurrent or refractory brain tumors: Toxicity and efficacy trends","volume":"59","author":"Couec","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"B77","unstructured":"Stereotactic radiosurgery (SRS) and stereotactic body radiotherapy (SBRT) [Internet]2021"},{"key":"B78","unstructured":"Stereotactic radiosurgery [Internet]2022"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2004.12.081","article-title":"Fractionated stereotactic radiotherapy of optic pathway gliomas: Tolerance and long-term outcome","volume":"62","author":"Combs","year":"2005","journal-title":"Int J Radiat Oncol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3171\/2016.8.GKS161432","article-title":"Single-session gamma knife radiosurgery for optic pathway\/hypothalamic gliomas","volume":"125","author":"El-Shehaby","year":"2016","journal-title":"J Neurosurg"},{"key":"B81","volume-title":"Medicine. radiosurgery","author":"Hopkins","year":"2022"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2018.03.056","article-title":"Proton stereotactic radiosurgery for brain metastases: A single-institution analysis of 370 patients","volume":"101","author":"Atkins","year":"2018","journal-title":"Int J Radiat Oncol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2019.01.078","article-title":"Outcomes following proton therapy for pediatric low-grade glioma","volume":"104","author":"Indelicato","year":"2019","journal-title":"Int J Radiat Oncol"},{"key":"B84","unstructured":"ShielW What are the side effects of stereotactic radiosurgery?2022"},{"key":"B85","unstructured":"Stereotactic radiosurgery [Internet]2022"}],"container-title":["Frontiers in Ophthalmology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fopht.2022.992673\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T00:30:45Z","timestamp":1676939445000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fopht.2022.992673\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,29]]},"references-count":85,"alternative-id":["10.3389\/fopht.2022.992673"],"URL":"https:\/\/doi.org\/10.3389\/fopht.2022.992673","relation":{},"ISSN":["2674-0826"],"issn-type":[{"value":"2674-0826","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,29]]},"article-number":"992673"}}